A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
Srividya Kotapati, PharmD
Advertisement
Articles by Srividya Kotapati, PharmD
Advertisement
Latest Updated Articles
- An Expanded Portfolio of Survival Metrics for Assessing Anticancer Agents
Published: January 17th 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5
